Catalyst Wire Dossier Catalyst Wire Dossier

voxilaprevir + sofosbuvir/velpatasvir fixed-dose combination

· Gilead Sciences
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for voxilaprevir + sofosbuvir/velpatasvir fixed-dose combination, covering 2017-12-08 to 2017-12-08. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection [Phase 2]

See pricing